Statins and prostate cancer risk: a case-control study (Q34433638)

2 August 2017

Statins and prostate cancer risk: a case-control study (English)

1 reference

2 August 2017

1 reference

1

Jackilen Shannon

1 reference

2 August 2017

Selome Tewoderos

2

1 reference

2 August 2017

Mark Garzotto

3

1 reference

2 August 2017

Tomasz M Beer

4

1 reference

2 August 2017

Rhianna Derenick

5

1 reference

2 August 2017

Amy Palma

6

1 reference

2 August 2017

Paige E Farris

7

1 reference

2 August 2017

language of work or name

English

0 references

publication date

13 July 2005

1 reference

American Journal of Epidemiology

2 August 2017

1 reference

2 August 2017

162

1 reference

2 August 2017

4

1 reference

2 August 2017

318-325

1 reference

2 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Do statins cause cancer? A meta-analysis of large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Statin use and cancer risk in the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Statin use and the risk of breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

Lipid rafts: bringing order to chaos

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FAJE%2FKWI203

21 January 2018

Identifiers

DOI

10.1093/AJE/KWI203

1 reference

2 August 2017

1 reference